The heat shock protein 90 inhibitor 17-AAG suppresses growth and induces apoptosis in human cholangiocarcinoma cells

Clinical and Experimental Medicine

Volumn 13, Issue 4, 2013, Pages 323-328

  Zhang, Jianjun ^a   Zheng, Zhichao ^a   Zhao, Yan ^a   Zhang, Tao ^a   Gu, Xiaohu ^a   Yang, Wei ^a  

^a LIAONING CANCER HOSPITAL AND INSTITUTE   (China)

Author keywords

17 AAG; Apoptosis; Cell cycle arrest; Cholangiocarcinoma; HSP90

Indexed keywords

CASPASE 3; CYCLIN B1; HEAT SHOCK PROTEIN 90 INHIBITOR; NICOTINAMIDE ADENINE DINUCLEOTIDE ADENOSINE DIPHOSPHATE RIBOSYLTRANSFERASE; PROTEIN BCL 2; SURVIVIN; TANESPIMYCIN;

APOPTOSIS; ARTICLE; BILE DUCT CARCINOMA; CANCER CELL CULTURE; CANCER INHIBITION; CELL CYCLE; CELL PROLIFERATION; CONTROLLED STUDY; DRUG MECHANISM; ENZYME ACTIVITY; G2 PHASE CELL CYCLE CHECKPOINT; HUMAN; HUMAN CELL; M PHASE CELL CYCLE CHECKPOINT; PRIORITY JOURNAL; PROTEIN EXPRESSION;

ANTINEOPLASTIC AGENTS; APOPTOSIS; BENZOQUINONES; BLOTTING, WESTERN; CELL CYCLE; CELL LINE, TUMOR; CELL PROLIFERATION; CELL SURVIVAL; CHOLANGIOCARCINOMA; FLOW CYTOMETRY; FORMAZANS; GENE EXPRESSION PROFILING; HSP90 HEAT-SHOCK PROTEINS; HUMANS; LACTAMS, MACROCYCLIC; STAINING AND LABELING; TETRAZOLIUM SALTS; THIAZOLES;

EID: 84888354685     PISSN: 15918890     EISSN: 15919528     Source Type: Journal    
DOI: 10.1007/s10238-012-0208-3     Document Type: Article

References (32)

1. Gatto M, Bragazzi MC, Semeraro R, Napoli C, Gentile R, Torrice A, Gaudio E, Alvaro D (2010) Cholangiocarcinoma: update and future perspectives. Dig Liver Dis 42(4):253-260. doi: 10.1016/j.dld.2009.12.008
2. Khan SA, Thomas HC, Davidson BR, Taylor-Robinson SD (2005) Cholangiocarcinoma. Lancet 366(9493):1303-1314. doi: 10.1016/S0140-6736(05) 67530-7 (Pubitemid 41416587)
3. Petrowsky H, Hong JC (2009) Current surgical management of hilar and intrahepatic cholangiocarcinoma: the role of resection and orthotopic liver transplantation. Transplant Proc 41(10):4023-4035. doi: 10.1016/j.transproceed. 2009.11.001
4. Nakeeb A, Pitt HA, Sohn TA, Coleman J, Abrams RA, Piantadosi S, Hruban RH, Lillemoe KD, Yeo CJ, Cameron JL (1996) Cholangiocarcinoma. A spectrum of intrahepatic, perihilar, and distal tumors. Ann Surg 224(4):463-473 (discussion 473-465) (Pubitemid 26337555)
5. Anderson C, Kim R (2009) Adjuvant therapy for resected extrahepatic cholangiocarcinoma: a review of the literature and future directions. Cancer Treat Rev 35(4):322-327. doi: 10.1016/j.ctrv.2008.11.009
6. Pearl LH, Prodromou C, Workman P (2008) The Hsp90 molecular chaperone: an open and shut case for treatment. Biochem J 410(3):439-453. doi: 10.1042/BJ20071640 (Pubitemid 351429015)
7. Pratt WB, Morishima Y, Osawa Y (2008) The Hsp90 chaperone machinery regulates signaling by modulating ligand binding clefts. J Biol Chem 283(34):22885-22889. doi: 10.1074/jbc.R800023200
8. Zhao R, Davey M, Hsu YC, Kaplanek P, Tong A, Parsons AB, Krogan N, Cagney G, Mai D, Greenblatt J, Boone C, Emili A, Houry WA (2005) Navigating the chaperone network: an integrative map of physical and genetic interactions mediated by the hsp90 chaperone. Cell 120(5):715-727. doi: 10.1016/j.cell.2004. 12.024 (Pubitemid 40343082)
9. McClellan AJ, Xia Y, Deutschbauer AM, Davis RW, Gerstein M, Frydman J (2007) Diverse cellular functions of the Hsp90 molecular chaperone uncovered using systems approaches. Cell 131(1):121-135. doi: 10.1016/j.cell.2007.07.036 (Pubitemid 47498528)
10. Bagatell R, Whitesell L (2004) Altered Hsp90 function in cancer: a unique therapeutic opportunity. Mol Cancer Ther 3(8):1021-1030 (Pubitemid 39199597)
11. Whitesell L, Lindquist SL (2005) HSP90 and the chaperoning of cancer. Nat Rev Cancer 5(10):761-772. doi: 10.1038/nrc1716 (Pubitemid 41400776)
12. Isaacs JS, Xu W, Neckers L (2003) Heat shock protein 90 as a molecular target for cancer therapeutics. Cancer Cell 3(3):213-217. doi: 10.1016/S1535-6108(03)00029-1 (Pubitemid 37443877)
13. Grenert JP, Sullivan WP, Fadden P, Haystead TA, Clark J, Mimnaugh E, Krutzsch H, Ochel HJ, Schulte TW, Sausville E, Neckers LM, Toft DO (1997) The amino-terminal domain of heat shock protein 90 (hsp90) that binds geldanamycin is an ATP/ADP switch domain that regulates hsp90 conformation. J Biol Chem 272(38):23843-23850 (Pubitemid 27410964)
14. Banerji U (2009) Heat shock protein 90 as a drug target: some like it hot. Clin Cancer Res 15(1):9-14. doi: 10.1158/1078-0432.CCR-08-0132
15. Gimenez Ortiz A, Montalar Salcedo J (2010) Heat shock proteins as targets in oncology. Clin Transl Oncol 12(3):166-173
16. Francis LK, Alsayed Y, Leleu X, Jia X, Singha UK, Anderson J, Timm M, Ngo H, Lu G, Huston A, Ehrlich LA, Dimmock E, Lentzsch S, Hideshima T, Roodman GD, Anderson KC, Ghobrial IM (2006) Combination mammalian target of rapamycin inhibitor rapamycin and HSP90 inhibitor 17-allylamino-17-demethoxygeldanamycin has synergistic activity in multiple myeloma. Clin Cancer Res 12(22):6826-6835. doi: 10.1158/1078-0432.CCR-06-1331 (Pubitemid 44876853)
17. Georgakis GV, Li Y, Rassidakis GZ, Martinez-Valdez H, Medeiros LJ, Younes A (2006) Inhibition of heat shock protein 90 function by 17-allylamino-17- demethoxy-geldanamycin in Hodgkin's lymphoma cells down-regulates Akt kinase, dephosphorylates extracellular signal-regulated kinase, and induces cell cycle arrest and cell death. Clin Cancer Res 12(2):584-590. doi: 10.1158/1078-0432. CCR-05-1194 (Pubitemid 43166153)
18. Biamonte MA, Van de Water R, Arndt JW, Scannevin RH, Perret D, Lee WC (2010) Heat shock protein 90: inhibitors in clinical trials. J Med Chem 53(1):3-17. doi: 10.1021/jm9004708
19. Ronnen EA, Kondagunta GV, Ishill N, Sweeney SM, Deluca JK, Schwartz L, Bacik J, Motzer RJ (2006) A phase II trial of 17-(Allylamino)-17- demethoxygeldanamycin in patients with papillary and clear cell renal cell carcinoma. Invest New Drugs 24(6):543-546. doi: 10.1007/s10637-006-9208-z (Pubitemid 44273031)
20. Munster PN, Srethapakdi M, Moasser MM, Rosen N (2001) Inhibition of heat shock protein 90 function by ansamycins causes the morphological and functional differentiation of breast cancer cells. Cancer Res 61(7):2945-2952 (Pubitemid 32691939)
21. Gossett DR, Bradley MS, Jin X, Lin J (2005) 17-Allyamino-17- demethoxygeldanamycin and 17-NN-dimethyl ethylene diamine-geldanamycin have cytotoxic activity against multiple gynecologic cancer cell types. Gynecol Oncol 96(2):381-388. doi: 10.1016/j.ygyno.2004.10.009 (Pubitemid 40127138)
22. Lang SA, Klein D, Moser C, Gaumann A, Glockzin G, Dahlke MH, Dietmaier W, Bolder U, Schlitt HJ, Geissler EK, Stoeltzing O (2007) Inhibition of heat shock protein 90 impairs epidermal growth factor-mediated signaling in gastric cancer cells and reduces tumor growth and vascularization in vivo. Mol Cancer Ther 6(3):1123-1132. doi: 10.1158/1535-7163.MCT-06-0628 (Pubitemid 46554583)
23. Watanabe G, Behrns KE, Kim JS, Kim RD (2009) Heat shock protein 90 inhibition abrogates hepatocellular cancer growth through cdc2-mediated G2/M cell cycle arrest and apoptosis. Cancer Chemother Pharmacol 64(3):433-443. doi: 10.1007/s00280-008-0888-2
24. Wu X, Wanders A, Wardega P, Tinge B, Gedda L, Bergstrom S, Sooman L, Gullbo J, Bergqvist M, Hesselius P, Lennartsson J, Ekman S (2009) Hsp90 is expressed and represents a therapeutic target in human oesophageal cancer using the inhibitor 17-allylamino-17-demethoxygeldanamycin. Br J Cancer 100(2):334-343. doi: 10.1038/sj.bjc.6604855
25. Mahalingam D, Swords R, Carew JS, Nawrocki ST, Bhalla K, Giles FJ (2009) Targeting HSP90 for cancer therapy. Br J Cancer 100(10):1523-1529. doi: 10.1038/sj.bjc.6605066
26. Bagatell R, Gore L, Egorin MJ, Ho R, Heller G, Boucher N, Zuhowski EG, Whitlock JA, Hunger SP, Narendran A, Katzenstein HM, Arceci RJ, Boklan J, Herzog CE, Whitesell L, Ivy SP, Trippett TM (2007) Phase I pharmacokinetic and pharmacodynamic study of 17-N-allylamino-17-demethoxygeldanamycin in pediatric patients with recurrent or refractory solid tumors: a pediatric oncology experimental therapeutics investigators consortium study. Clin Cancer Res 13(6):1783-1788. doi: 10.1158/1078-0432.CCR-06-1892 (Pubitemid 46952946)
27. Ramanathan RK, Trump DL, Eiseman JL, Belani CP, Agarwala SS, Zuhowski EG, Lan J, Potter DM, Ivy SP, Ramalingam S, Brufsky AM, Wong MK, Tutchko S, Egorin MJ (2005) Phase I pharmacokinetic-pharmacodynamic study of 17-(allylamino)-17- demethoxygeldanamycin (17AAG, NSC 330507), a novel inhibitor of heat shock protein 90, in patients with refractory advanced cancers. Clin Cancer Res 11(9):3385-3391. doi: 10.1158/1078-0432.CCR-04-2322 (Pubitemid 40627891)
28. Hostein I, Robertson D, DiStefano F, Workman P, Clarke PA (2001) Inhibition of signal transduction by the Hsp90 inhibitor 17-allylamino-17- demethoxygeldanamycin results in cytostasis and apoptosis. Cancer Res 61(10):4003-4009 (Pubitemid 32720963)
29. Burger AM, Fiebig HH, Stinson SF, Sausville EA (2004) 17-(Allylamino)-17-demethoxygeldanamycin activity in human melanoma models. Anticancer Drugs 15(4):377-387 (Pubitemid 38526763)
30. Burlacu A (2003) Regulation of apoptosis by Bcl-2 family proteins. J Cell Mol Med 7(3):249-257 (Pubitemid 37372044)
31. Okamoto J, Mikami I, Tominaga Y, Kuchenbecker KM, Lin YC, Bravo DT, Clement G, Yagui-Beltran A, Ray MR, Koizumi K, He B, Jablons DM (2008) Inhibition of Hsp90 leads to cell cycle arrest and apoptosis in human malignant pleural mesothelioma. J Thorac Oncol 3(10):1089-1095. doi: 10.1097/JTO. 0b013e3181839693
32. Dash BC, El-Deiry WS (2005) Phosphorylation of p21 in G2/M promotes cyclin B-Cdc2 kinase activity. Mol Cell Biol 25(8):3364-3387. doi: 10.1128/MCB.25.8.3364-3387.2005 (Pubitemid 40464336)